Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

BACKGROUND: A phase-III trial showed the non-inferiority of oral capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) in terms of efficacy in first-line treatment of metastatic colorectal cancer. A secondary objective was to compare the quality of life (QoL)...

Descripción completa

Detalles Bibliográficos
Autores principales: Conroy, T, Hebbar, M, Bennouna, J, Ducreux, M, Ychou, M, Llédo, G, Adenis, A, Faroux, R, Rebischung, C, Kockler, L, Douillard, J Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813741/
https://www.ncbi.nlm.nih.gov/pubmed/19920832
http://dx.doi.org/10.1038/sj.bjc.6605442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813741/
https://www.ncbi.nlm.nih.gov/pubmed/19920832
http://dx.doi.org/10.1038/sj.bjc.6605442

Ejemplares similares